AFMID
Kynurenine formamidase
Also known as: DKFZp686F03259, KF, KFA_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q63HM1
- Gene
- AFMID
- Ensembl
- ENSG00000183077
- Chromosome
- 17
- Canonical length
- 303 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted intracellular proteins
- Subcellular location
- Mitochondria
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Predicted to enable arylformamidase activity. Predicted to be involved in L-tryptophan catabolic process to kynurenine. Predicted to be located in cytosol and nucleus. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
303 residues, UniProt reviewed canonical sequence.
>Q63HM1|AFMID
1 MMDVSGVGFP SKVPWKKMSA EELENQYCPS RWVVRLGAEE ALRTYSQIGI EATTRARATR
61 KSLLHVPYGD GEGEKVDIYF PDESSEALPF FLFFHGGYWQ SGSKDESAFM VHPLTAQGVA
121 VVIVAYGIAP KGTLDHMVDQ VTRSVAFVQK RYPSNKGIYL CGHSAGAHLA AMMLLADWTK
181 HGVTPNLRGF FLVSGVFDLE PIVYTSQNVA LQLTLEDAQR NSPQLKVAQA QPVDPTCRVL
241 VVVGQFDSPE FHRQSWEFYQ TLCQGEWKAS FEELHDVDHF EIVENLTQKD NVLTQIILKT
301 IFQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AFMID can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.23
- Highest tissue expression
- 167 nTPM
Expression across tissuesHPA
Tissue
- liver: 167 nTPM
- kidney: 99 nTPM
- spinal cord: 64 nTPM
- breast: 63 nTPM
- cerebellum: 59 nTPM
- pancreas: 57 nTPM
Single-cell type
- proximal tubule cells: 250 nCPM
- enterocytes: 231 nCPM
- colonocytes: 224 nCPM
- renal collecting duct principal cells: 173 nCPM
- breast lactating cells: 151 nCPM
- hepatocytes: 148 nCPM
Immune cell
- intermediate monocyte: 17 nTPM
- non-classical monocyte: 11 nTPM
- myeloid DC: 7.8 nTPM
- classical monocyte: 6.7 nTPM
- memory B-cell: 5.6 nTPM
- plasmacytoid DC: 5.1 nTPM
Brain region
- white matter: 184 nTPM
- basal ganglia: 108 nTPM
- medulla oblongata: 107 nTPM
- midbrain: 100 nTPM
- cerebral cortex: 99 nTPM
- thalamus: 94 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.1
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.12
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- arylformamidase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Alpha/beta hydrolase fold-3
- Alpha/Beta hydrolase fold
- GDXG lipolytic enzyme
- alpha/beta hydrolase fold
- Kynurenine formamidase, vertebrates/fungi-type
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AFMID as an antibody target. Whether an autoantibody or antibody against AFMID could matter depends on whether native AFMID is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AFMID is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label AFMID as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...